In This Section


Beginning at 3:00 p.m. on Friday, April 8, and continuing all day Saturday, April 9, 2022, the AACR Annual Meeting Program will include Educational Sessions and Methods Workshops. The program on Saturday will conclude with the Precancer Discovery Science Plenary Session. The Opening Ceremony and the Opening Plenary Session will take place on Sunday morning, April 10. The meeting will conclude at 1:30 p.m. on Wednesday, April 13.

Plenary Sessions

Saturday, April 9, 2022
Precancer Discovery Science

Chair: Catriona H.M. Jamieson, UCSD Moores Cancer Center, La Jolla, CA

  • Avrum E. Spira, Johnson & Johnson and Boston University Medical Center, Boston, MA
  • Rebecca Fitzgerald, Hutchison/MRC Research Center, Cambridge, United Kingdom
  • Veronica Kinzler, The Francis Crick Institute, London, United Kingdom
  • Susan M. Domchek, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

Sunday, April 10, 2022
Opening Plenary Session: Decoding Cancer Complexity, Integrating Science, Transforming
Patient Outcomes
Chair: Marcia R. Cruz-Correa,
University of Puerto Rico Comprehensive Cancer Center, San Juan, PR

  • Michael R. Stratton, Wellcome Trust Sanger Institute, Cambridge, United Kingdom
  • James M. Crawford, Yale University, West Haven, CT
  • Marcia C. Haigis, Harvard Medical School, Boston, MA
  • Nickolas Papadopoulos, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
  • Franziska Michor, Dana-Farber Cancer Institute, Boston, MA
  • Charles L. Sawyers, Memorial Sloan Kettering Cancer Center, New York, NY

Monday, April 11, 2022
Decoding Cancer Health Disparities: Integration of Complex Data and Diversity to Achieve Equity
Chair: Mariana C. Stern, USC Norris Comprehensive Cancer Center, Los Angeles, CA

  • Yu Shyr, Vanderbilt University Medical Center, Nashville, TN
  • Matthew L. Meyerson, Dana-Farber Cancer Institute, Boston, MA
  • Olusegun I. Alatise, Obafemi Awolowo University, Ile-Ife, Nigeria
  • Andy Futreal, The University of Texas MD Anderson Cancer Center, Houston, TX
  • Cheryl L. Willman, Mayo Clinic Comprehensive Cancer Center, Rochester, MN; and University of New Mexico Comprehensive Cancer Center, Albuquerque, NM

Tuesday, April 12, 2022
Precision Medicine for Immuno-oncology and the Promise for the Future
Chair: Carl H. June, University of Pennsylvania, Philadelphia, PA

  • Ton N. Schumacher, Netherlands Cancer Institute, Haarlem, The Netherlands
  • Thomas F. Gajewski, University of Chicago, Chicago, IL
  • Luis A. Diaz, Memorial Sloan Kettering Cancer Center, New York, NY
  • Shannon J. Turley, Genentech, Inc., South San Francisco, CA

Wednesday, April 13, 2022
Tumor Evolution and Therapeutic Resistance
Chair: Anna D. Barker, Ellison Institute for Transformative Medicine, Los Angeles, CA

  • Emmanuelle Passegué, Columbia University Irving Medical Center, New York, NY
  • Peter J. Campbell, Wellcome Trust Sanger Institute, Cambridge, United Kingdom
  • Christine A. Iacobuzio-Donahue, Memorial Sloan Kettering Cancer Center, New York, NY
  • Nicholas E. Navin, The University of Texas MD Anderson Cancer Center, Houston, TX
  • Charles Swanton, The Francis Crick Institute, London, United Kingdom

AACR Annual Meeting 2022 Highlights: Vision for the Future 
Chair: Marcia R. Cruz-Correa,
 University of Puerto Rico Comprehensive Cancer Center, San Juan, PR

  • Danny R. Welch, University of Kansas Cancer Center, Kansas City, KS
  • Jennifer A. Doherty, University of Utah Huntsman Cancer Institute, Salt Lake City, UT
  • Lillian L. Siu, UHN Princess Margaret Cancer Center, Toronto, ON, Canada

Major Symposia

  • Adipose Tissue as a Driver of Carcinogenesis
  • Aging and the Tumor Microenvironment’s Impact on Minimal Residual Disease and Cancer Recurrence
  • Artificial Intelligence in Cancer Research and Care
  • Bone Metastasis
  • Cancer Evolution Biomarkers
  • Cancer Stem Cell Metabolism, Proteostasis, and Metastasis
  • Cancer Vaccines: New Developments and Clinical Response
  • Challenging Drug Targets
  • Clinical Progress with CD3 Bispecifics
  • Digital and Computational Histopathology: Taking Cancer Diagnostics to the Cutting Edge
  • Epigenetic Alterations as Cancer Therapeutic Targets
  • Epigenome Biology and Cancer
  • Extracellular Matrix Remodeling in Cancer
  • Extrachromosomal DNA: Origins and Significance
  • Genome Instability as a Driver of Cancer Evolution
  • Germline Mutations as Drug Targets
  • Identification of Cancer Dependencies
  • Immunoprevention and Clinical Trials
  • Immunotherapy for Solid Tumors and Blood Cancers in Adult and Pediatric Patients
  • Liquid Biopsy: From Discovery to Clinical Application
  • Macroenvironmental and Microenvironmental Drivers of Cancer Stem Cell Generation
  • Mechanisms of Cancer Stem Cell Immune Evasion
  • Mechanisms of Protein Degradation Chemistries for Cancer Therapy
  • Mechanisms of Structural Mutations in Cancer
  • Metabolism of the Tumor Microenvironment
  • Metastatic Organotropism
  • Microdosing and Drug Delivery
  • Modern Synthetic Lethality Strategies in Targeting the DNA Damage Response and Beyond: Moving beyond PARP and BRCA
  • Multiomics Approaches for Novel Oncopathogen Discovery and Related Mechanisms
  • Myeloid Targets to Enhance Therapeutic Antitumor Immunity
  • Nerves, Cancer, and Immunity
  • Novel Genetic Screening Strategies to Identify Therapeutic Targets in Cancer
  • Novel Mechanisms for Targeting KRAS
  • Pathophysiology and New Treatments for Cancer-Associated Thrombosis
  • Physical Aspects of Cancer and Physical Sciences of Oncology
  • Predictive Biomarkers for Precision Radiation Oncology
  • Profiling Molecular Proximity in Cancer Research
  • Radiation and Immunotherapy
  • The Science of Survivorship
  • Screening, Detecting, Intervening Earlier in Clinical Care of Underserved Populations
  • Targeting Noncancer Syndromes with Cancer Drugs
  • The Crossroads between Epigenetic Regulation and Metabolism in Cancer
  • Tumor Dormancy
  • Understanding Microbe–Tumor Interactions in Health and Disease: From Basic Mechanisms to Applied Microbial-Based Cancer Therapy

Advances in Diagnostics and Therapeutics

  • Adjuvant versus Neoadjuvant Immunotherapy
  • Adoptive Cellular Therapy: Treatment for the Masses
  • Cancer Metabolic Phenotypes: A Precision Medicine Perspective for Radiation Oncology?
  • Clinical to Genetic Monitoring for Hereditary Cancers
  • Deep Learning for Cancer Imaging
  • Functional Precision Medicine
  • How Should Clonal Hematopoiesis Impact Cancer Treatment Decisions?
  • Interpreting and Building Trust in Artificial Intelligence Models
  • Machine Learning to Translate the Cancer Genome and Epigenome
  • New Developments in Immunotherapy: Targeting Cytokines
  • Next-Generation Costimulatory Receptor Agonists in Combination with CD3 Bispecific Antibodies
  • Peptide–Peptide Interaction Inhibitors in Cancer Therapeutics
  • Targeting Transcription Factors
  • Technologies to Understand Malignant Clonal Behavior at Single Cell Resolution
  • Theranostics for Patient Care

Advances in Organ Site Research

  • Advances in Bladder Cancer
  • Advances in Glioblastoma Cancer Research and Cancer Care
  • Advances in Neuroblastoma Research
  • Advances in Ovarian Cancer Screening and Treatment
  • Bone Marrow Immune Microenvironment
  • Breast Cancer Genomics in Latin America
  • Gastric Cancer: From Biology to Therapy
  • Models for Rare Cancers
  • New Targets for Prostate Cancer
  • Pediatric Tumors
  • Progress in Understanding Nonalcoholic Fatty Liver Disease-Induced Liver Cancer and Associated Disparities
  • Triple Negative Breast Cancer: Molecular Insights and Treatment Advances
  • Understanding Microbe–Tumor Relationships in Colorectal Cancer

Advances in Population Sciences

  • Functional Role of Long Tail Coding and Noncoding Mutations in Cancer
  • Impact of Off-Label Therapies in Cancer Care and Outcomes across Populations
  • Where You Live Matters: From Biological to Social Determinants of Cancer Outcomes

Advances in Prevention Research

  • Multicancer Screening Tests
  • The Role of Infection in Cancer
  • Tobacco and Smokeless Tobacco

Advances in the Science of Cancer Health Disparities

  • Implementation Science for Bridging Health Disparities
  • Molecular Epidemiology of Stress and Discrimination and Cancer Outcomes
  • Obesity and Health Disparities in Cancer


  • Addressing Health Disparities and Patient Distrust
  • Advances in Lung Cancer
  • Breaking Down Silos: If We Did It during the COVID Pandemic, Why Not for Cancer?
  • Choosing What Immuno-oncology Combinations to Use for Your Patient
  • How Can We Address the Disparate Risk of Cervical Cancer in Vulnerable Populations?
  • How Have GWAS/EWAS Studies Impacted Cancer Research?
  • Impact of Telehealth on Cancer Care Delivery
  • Oligometastatic Disease
  • Pancreas Cancer: Why Are We Moving So Slowly?
  • Precision Oncology for Pediatric Cancer
  • Untangling the Mechanisms of Resistance to Immune Checkpoint Blockade
  • Vaccine Effectiveness in Cancer Patients with Immunotherapy
  • What Is the Causal Link between Race and Early Onset of Colon Cancer?

Educational Sessions

  • Advances in Ligand Discovery Against Poorly Tractable Targets
  • Advances to SHP2 for RAS inhibition
  • AI: Introduction of Interpretation of Models, Transfer Learning, and Imaging for Basic Biologists
  • Big Data Resources in Pediatric Cancer
  • Cancer Dormancy and Immune Regulation
  • Cancer Survivorship
  • Chemistry to the Clinic: Part 1 of 3: Targeting Ras Beyond G12C
  • Chemistry to the Clinic: Part 2 of 3: Progress in Small Molecule Cancer Immunology Therapy
  • Chemistry to the Clinic: Part 3 of 3: Evolution of Computational Tools and Strategies to Advance Oncology Drug Development
  • Combination Therapeutic Strategies in the Treatment of Lung Cancer
  • Considerations of Tissue-Specific Aging in Cancer Research
  • Defining Cancer Evolution Types and Their Impact on Cancer
  • Degrading Undruggable Targets in Pediatric Cancer
  • Developing Genomic Classifiers of Cancer
  • Diet, Microbiota, and Cancer Immunotherapies
  • Drug Resistance: Challenges and Prospects
  • Examining Tissue Specific Stroma to Increase Therapeutic Opportunities in Metastasis
  • Immunocytokines: Strategies for Drug Delivery and Tissue Targeting
  • Implementation Science: Efforts to Improve Cancer Health Equity
  • Increasing Diverse Participation in Biomedical Cancer Research: Best Practices and Innovation
  • Measuring Lifestyle Using Biomarkers Indicating Favorable Effects of Diet and Dietary Supplements
  • Metabolism, Inflammation, and Immunotherapy
  • Minimal Residual Disease in Solid Tumors: What Does It Mean and How Should It Guide Treatment Decision-Making?
  • Natural Killer (NK) Cells: From Cancer Orchestrators to Car-NK Therapy
  • Next Frontiers in Neoadjuvant Immunotherapy: Diversification and Durability of the Immune Response
  • Novel Antibody Drug Conjugates
  • Novel Strategies to Target the Cyclin-Dependent Kinases
  • Organoids in Cancer Research
  • Outreach and Education in COVID-19 Times: Opportunities and Lessons Learned
  • Pathology for Cancer Researchers
  • Polygenic Risk Scores: Considerations for Development and Evaluation
  • Precision Cancer Prevention
  • Predictive Biomarkers for Immunotherapy
  • Radiotheranostics for Cancer
  • Regenerative Response of Irradiated Tissues: Models and Signaling Pathways
  • Roles of RNA in Cancer and Cancer Therapies
  • Sex Matters: Understanding the Effect of Sex on Shaping the Tumor and Response to Cancer Therapy
  • Single Cell Biology in Scale and Spatial Genomics
  • Systems Biology Approaches to Cancer
  • The Epigenetics of Cancer
  • The Evolving Crosstalk in the Cancer Stem Cell Niche
  • The Importance of Surgeon Engagement for Translational Cancer Research
  • The Science Behind Cytokine Release Syndrome
  • Tumor Immunology and Immunotherapy for Nonimmunologists: The Immunological Bases of Durable Responses to Cancer Immunotherapy
  • Understanding Cell Death in Cancer Therapy
  • Unfolding the Unfolded Protein Response (UPR) as a Diagnostic and Therapeutic Target in Cancer
  • Using Patient-Reported Outcomes in Clinical and Population-Based Research
  • Utilizing Chemical Probes for the Validation of Cancer Targets

Methods workshops

  • Artificial Intelligence in Cancer Imaging
  • Advances in Nanotechnologies and Therapeutics
  • Biobanks: Why Do You Need Them in Your Cancer Research Program
  • Clinical Trial Design: Part 1
  • Clinical Trial Design: Part 2
  • Clinical Trial Design: Part 3
  • Design and Analysis of Real-World Data for Cancer Research
  • From Molecular Glues to Interfacial Binders: Targeting Protein Complexes with Small Molecule Inhibitors
  • Introduction to Network Biology and Knowledge Graphs in Cancer Research
  • Methods and Implications for Using Race and Ancestry in Cancer Research
  • Mitochondrial Dynamics
  • New Concepts in Unraveling the 3D Genome
  • Spatial Analysis on the Tumor Microenvironment
  • Spatial Transcriptomics and Cellular Imaging
  • Technical Challenges of Liquid Biopsy Analyses